Percutaneous intervention for the treatment of hypoplastic aortoiliac syndrome

Brian L Walton1, Kathy Dougherty, Ali Mortazavi

  • 1Department of Cardiology, St. Luke's Episcopal Hospital and Texas Heart Institute, Houston, Texas 77030, USA.

Hypoplastic aortoiliac syndrome (HAIS) occurs in young women and is characterized by a small infrarenal aorta with a hypoplastic iliofemoral arterial system and advanced atherosclerotic disease. Of 304 aortoiliac interventions (AoI), 30 female patients (mean age, 50 +/- 5 years) had HAIS. HAIS patients were less likely to have coronary disease (33% vs. 88%; P < 0.0001) or diabetes (10% vs. 42%; P < 0.001) compared to their AoI counterparts. Twenty-three patients (73%) had hyperlipidemia with mean cholesterol of 287 +/- 42 mg/dl. Twenty-eight patients (93%) were successfully treated with AoI. The ankle/brachial indices improved from pre-AoI ABI of 0.55 +/- 0.1 to post-AoI ABI of 0.99 +/- 0.1. Complications included one groin hematoma and one case of thrombosis. Follow-up averaged 31 months (range, 3-91 months) with an early (less than 12 months) restenosis rate of 7% and late (greater than 12 months) restenosis of 21%. One patient (3%) required surgical revascularization for persistent symptoms. Percutaneous treatment of HAIS is an alternative to surgical revascularization with satisfactory long-term results.